Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL887980 | 0.92 | ADORA2A (0.39) | PRMT6ADORA3ADORA2AADORA1 | |
| SCHEMBL888000 | 0.81 | ADORA3 (0.43) | PRMT6ADORA3ADORA2AADORA1P2RY12 | |
| SCHEMBL7873199 | 0.80 | PRMT6 (0.40) | PRMT6ADORA3ADORA2AADORA1P2RY12 | |
| SCHEMBL5354472 | 0.79 | ADORA3 (0.41) | PRMT6ADORA3ADORA2AADORA1P2RY12 | |
| SCHEMBL2112012 | 0.78 | ADORA3 (0.43) | PRMT6ADORA3P2RY12 | |
| SCHEMBL439195 | 0.78 | PRMT5 (0.45) | ADORA3ADORA2AP2RY12 | |
| SCHEMBL7523809 | 0.76 | PRMT5 (0.45) | ADORA3ADORA2AP2RY12 | |
| SCHEMBL4434106 | 0.74 | ADORA2A (0.39) | PRMT6ADORA3ADORA2AADORA1P2RY12 | |
| SCHEMBL1070361 | 0.72 | ADORA2A (0.49) | PRMT6ADORA2AADORA1 | |
| SCHEMBL6839735 | 0.72 | ADORA2A (0.43) | PRMT6ADORA3ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431366-B2 | Modified oligonucleotides and applications thereof | APPLIED BIOSYSTEMS, LLC (US) | 2013-04-30 | — | — | US | disclosed |
| US-20110287431-A1 | MODIFIED OLIGONUCLEOTIDES AND APPLICATIONS THEREOF | Life Technologies Corporation (US) | 2011-11-24 | — | — | US | disclosed |
| US-7943752-B2 | Modified oligonucleotides and applications thereof | Applied Biosystems, L.L.C. (US) | 2011-05-17 | — | — | US | disclosed |
| US-20090226924-A1 | Modified Oligonucleotides and Applications Thereof | APPLERA CORPORATION | 2009-09-10 | — | — | US | disclosed |
| US-7517978-B1 | Modified oligonucleotides and applications thereof | APPLIED BIOSYSTEMS, LLC (US) | 2009-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090226924-A1 | Modified Oligonucleotides and Applications Thereof | RNGTT, POLRMT, POLM | PRMT6 3063/4885ADORA3 1849/4885ADORA2A 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.